# RLC Followed by CR-CHOP in Elderly Patients with Newly-diagnosed DEL

> **NCT06674096** · PHASE2 · RECRUITING · sponsor: **Zhejiang Cancer Hospital** · enrollment: 44 (estimated)

## Conditions studied

- Double-expressor Lymphoma

## Interventions

- **DRUG:** RLC-CRCHOP

## Key facts

- **NCT ID:** NCT06674096
- **Lead sponsor:** Zhejiang Cancer Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-11-06
- **Primary completion:** 2029-12-30
- **Final completion:** 2030-06-30
- **Target enrollment:** 44 (ESTIMATED)
- **Last updated:** 2024-11-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06674096

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06674096, "RLC Followed by CR-CHOP in Elderly Patients with Newly-diagnosed DEL". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06674096. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*